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OBJECTIVES: In contrast with other developed nations, life expectancy is decreasing in the United States, in part due
to increasing mortality from alcohol-associated liver disease (ALD). Up-to-date estimates of ALD
mortality are necessary for setting public health priorities to reverse this concerning trend.We therefore
aimed to assess current (2017) estimates of ALD mortality and temporal trends from 1999 to 2017.
METHODS: Using national data from the Centers for Disease Control and Prevention, we analyzed stratified ALD
mortality rates between 1999 and 2017.We determined the age-adjusted death rates, stratified by sex
and categorized by age, race/ethnicity, urbanization, and census region. We also identified statistically
significant changes in the annual rate difference (ARD), annual percentage change (APC), and average
APC in ALD mortality.
RESULTS: In2017,mortality fromALDwashigher thanany other year since1999with age-adjusted ratesof 13.1per
100,000 (95% confidence interval [CI] 12.9–13.3) in men and 5.6 per 100,000 (95% CI 5.4–5.7) in
women.Mortality was highest amongmen and women who were middle aged, Native American, and from
rural areas.Since2006,ALDmortality has increased in almostevery agegroupand racewith the exception
of non-Hispanic black men. Absolute increases in mortality rates have been particularly pronounced in
NativeAmericanwomen(2005–2017ARD0.8,95%CI0.6–0.9),non-Hispanic/whitemen(2006–2017
ARD 0.4, 95% CI 0.3–0.4), and non-Hispanic/white women (2013–2017 ARD 0.4, 95% CI 0.3–0.5).
DISCUSSION: Mortality from ALD is increasing over time in most demographic groups. Increased effort is needed to
develop targeted public health strategies to address high and increasing ALD mortality.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/AJG/B305, http://links.lww.com/AJG/B306
Am J Gastroenterol 2020;115:79–87. https://doi.org/10.14309/ajg.0000000000000442
INTRODUCTION
In 2017, the life expectancy of Americans decreased, running
counter to trends in the rest of the developed world (1). Although
overshadowed by the opioid epidemic, alcohol-associated liver
disease (ALD) has been identified as a contributing factor in de-
creasing life expectancies, particularly among non-Hispanicwhites
(2). Furthermore, health care expenditures for alcohol use disorder
(AUD) are estimated at $9 billion dollars annually, ALD accounts
for more inpatient health care costs than all other etiologies of
cirrhosis combined, andALD is now the leading indication for liver
transplantation (3–5).
Despite its considerable burden, ALD remains relatively
understudied and underfunded, possibly as a result of its social
stigma (6). The gap between the substantial burden of ALD
and the attention it garners underscores the importance of
accurate and up-to-date mortality estimates of ALD in the
United States. Previous publications found an increase in ALD
mortality, but these analyses did not stratify by sex or
disaggregate mortality by age and race (7,8). In addition,
a recent study on mortality from cirrhosis and hepatocellular
carcinoma in the United States focused on the relative changes
in ALD mortality (8). An in-depth assessment of current
mortality rates from ALD, including a focus on the absolute
changes in ALD mortality rates, and differences in ALD
mortality by age, sex, and race/ethnicity are essential to de-
velop targeted public health strategies.
To characterize the burden of ALD, we had 2 aims. First, we
evaluated the current (2017) estimates of ALD mortality
stratified by sex and subcategorized by age, race/ethnicity,
urbanization, and region. Second, we assessed temporal trends
in ALD mortality within these subgroups between 1999 and
2017.
METHODS
Using the Centers for Disease Control and Prevention Un-
derlying Cause of Death database, we analyzed ALD mortality
1Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA; 2Department of Epidemiology,
Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA; 3Division of Gastroenterology, Hepatology and Nutrition,
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. Correspondence: Anne F. Peery, MD, MSCR. E-mail: anne_peery@med.unc.edu.
Received April 2, 2019; accepted September 24, 2019; published online October 31, 2019
Hispanic and non-Hispanic ethnicities within the Native
American subgroup. For urbanization, we used the 2013 NCHS
Urban-Rural Classification Scheme for Counties. Large central
metro, large fringe metro, mediummetro, and small metro were
considered urban, whereas micropolitan and noncore were
classified as rural.
We assessed changes in annual mortality rate trends on both
the absolute scale (annual rate difference [ARD]) and relative
scale (annual percentage change [APC] and average APC),
using the National Cancer Institute’s Joinpoint program (ver-
sion 4.7.0.0, http://surveillance.cancer.gov/joinpoint). This
methodology for examining trends in mortality data has been
recommended by the National Cancer Institute and has been
used in previous publications (8,11–16). The Joinpoint pro-
gram is able to fit data on trends (e.g., ALDmortality over time)
into a model that identifies statistically significant changes in
trends (i.e., joinpoints). Additional information on the un-
derlying methodology is included in Supplementary Material
(see Supplementary Digital Content 1, http://links.lww.com/
AJG/B305).
Based on the joinpoints produced in the final models, we es-
timated ARD, APC, and average APC for the observed data,
overall and within each subgroup. SEs and 95% confidence
intervals (CIs) were estimated usingMonte Carlo simulationwith
4,500 iterations.






Overall 6,773 5.92 (5.78–6.06) 5.58 (5.44–5.72)
Age groups (y)
25–34 293 1.31 (1.16–1.46) —
35–44 831 4.05 (3.78–4.33) —
45–54 1,975 9.20 (8.79–9.61) —
55–64 2,376 10.93 (10.49–11.37) —
65–74 974 6.16 (5.78–6.55) —
75–84 256 3.08 (2.71–3.46) —
851 68 1.62 (1.26–2.06) —
Race/ethnicity
White/non-Hispanic 5,095 6.81 (6.62–7.00) 6.34 (6.15–6.52)
Black/non-Hispanic 573 3.98 (3.65–4.30) 3.74 (3.43–4.05)
Hispanic 684 4.08 (3.77–4.38) 4.23 (3.91–4.55)
Native American 344 24.68 (22.08–27.29) 24.48 (21.85–27.10)
Urbanization
Urban 5,668 5.77 (5.62–5.92) 5.44 (5.29–5.58)
Rural 1,105 6.87 (6.46–7.27) 6.54 (6.13–6.95)
Region
Northeast 823 4.00 (3.73–4.27) 3.77 (3.50–4.04)
Midwest 1,361 5.73 (5.43–6.03) 5.42 (5.12–5.72)
South 2,099 4.83 (4.62–5.03) 4.53 (4.33–4.73)
West 2,490 9.38 (9.01–9.75) 8.89 (8.53–9.25)
ALD, alcohol-associated liver disease; CI, confidence interval.
rates from 1999 to 2017 (9). This database is maintained by the 
National Center for Health Statistics (NCHS) and contains 
mortality and population counts for all US counties. Data are 
based on death certificates, each of which identifies a single un-
derlying cause of death selected from the conditions entered by 
a physician. When more than 1 cause or condition is entered by 
the physician, the underlying cause is determined by the sequence 
of conditions on the death certificate, rules of the International 
Classification of Diseases (ICD) system, and associated selection 
guidelines and modifications.
We included all patients with ALD (K70) listed as the un-
derlying cause of death, as identified by its corresponding ICD, 
10th Revision, Clinical Modification code (ICD-10). We excluded 
patients younger than 25 years because the number of deaths 
among individuals younger than 25 is too small to produce reli-
able estimates of mortality rates.
We stratified by sex and reported mortality overall and by 10-
year age groups, race/ethnicity, urbanization, and census region. 
Census regions are classified as Northeast, Midwest, South, and 
West according to the state of residence at the time of death (https://
wonder.cdc.gov/wonder/help/ucd.html#Census%20Regions).
Age adjustment was performed using methods proposed by the 
NCHS and was based on age distributions from the 2000 US census 
(10). Race/ethnicity was classified as white/non-Hispanic, black/
non-Hispanic, Hispanic, and Native American. We included both
RESULTS
High ALD mortality in men and increasing mortality rates in
both sexes
In 2017, the age-adjusted ALD mortality was 5.6 per 100,000
(95%CI 5.4–5.7) among all women and 13.1 per 100,000 (95%CI
12.9–13.3) inmen (Tables 1 and 2). For both sexes, these were the
highest annualmortality rates of any year between 1999 and 2017.
Among women, ALD mortality was stable between 1999 and
2006 (ARD 0.0, 95% CI 0.0–0.0) but increased significantly be-
tween 2006 and 2013 (ARD 0.2, 95% CI 0.1–0.2) and again be-
tween 2013 and 2017 by 0.3 per 100,000 annually (95% CI
0.2–0.4) (Figure 1 andTable 3). Amongmen,mortality fromALD
decreased between 1999 and 2006 by 0.1 per 100,000 annually
(95% CI 20.2 to 0.0) (Figure 1 and Table 4). Thereafter, ALD
mortality rates in men increased significantly by 0.3 per 100,000
annually (95% CI 0.3–0.4) from 2006 to 2017.
Increases in ALD highest in middle-aged individuals
In both men and women, ALD mortality was highest among
those aged 55–64 years (Figure 2). In this age group, the 2017
crude mortality rate was 10.9 per 100,000 (95% CI 10.5–11.4) for
women and 28.4 per 100,000 (95% CI 27.7–29.1) for men.
Women of all ages had statistically significant increases in ALD
mortality in recent years. The largest increase was seen in women
aged 55–64 years with an annual 0.6 per 100,000 increase (95%CI
0.5–0.6) from 2008 to 2017. From 1999 to the mid-2000s, ALD
mortality in men remained flat or decreased in every age group.
This trend has reversed in the last decade, with significant
increases in mortality in men of all age groups and the largest
increases in age 65–74 years from 2012 to 2017 (ARD 1.1, 95%
CI 0.8–1.4) and age 55–64 years from2004 to 2017 (ARD0.9, 95%
CI 0.8–0.9).
ALD mortality increases highest in Native Americans and non-
Hispanic whites
In 2017, age-adjusted ALD mortality was highest among Native
American men (34.1/100,000, 95% CI 31.0–37.2) and women
(24.5/100,000, 95% CI 21.9–27.1) followed by Hispanic men
(19.0/100,000, 95% CI 18.3–19.8) and white/non-Hispanic men
(13.2/100,000, 95% CI 12.9–13.5). Mortality was comparatively
lower among black/non-Hispanic women (3.7/100,000, 95% CI
3.4–4.1) and men (8.3/100,000, 95% CI 7.8–8.8).
In women, the largest increase in ALDmortality was seen in
Native Americans with an ARD of 0.8 (95% CI 0.6–0.9) from
2005 to 2017 (Figure 3).White/non-Hispanic women also have
steady increases in ALD mortality since 1999, with the largest
increases in more recent years (2013–2017 ARD 0.4, 95%
CI 0.3–0.5).






Overall 15,458 14.43 (14.21–14.66) 13.09 (12.88–13.30)
Age groups (y)
25–34 460 2.00 (1.82–2.18)
35–44 1,435 7.04 (6.68–7.41) —
45–54 3,811 18.23 (17.65–18.81) —
55–64 5,750 28.38 (27.65–29.12) —
65–74 3,002 21.63 (20.86–22.41) —
75–84 841 13.12 (12.24–14.01) —
851 159 6.97 (5.89–8.06) —
Race/ethnicity
White/non-Hispanic 10,807 15.30 (15.01–15.59) 13.19 (12.93–13.45)
Black/non-Hispanic 1,087 8.80 (8.27–9.32) 8.29 (7.78–8.80)
Hispanic 2,800 16.65 (16.03–17.26) 19.04 (18.30–19.78)
Native American 477 34.57 (31.47–37.68) 34.11 (31.02–37.21)
Urbanization
Urban 12,783 13.99 (13.74–14.23) 12.84 (12.61–13.07)
Rural 2,675 17.05 (16.41–17.70) 14.67 (14.09–15.26)
Region
Northeast 1,803 9.57 (9.13–10.01) 8.52 (8.12–8.93)
Midwest 2,913 13.01 (12.54–13.48) 11.69 (11.25–12.13)
South 5,420 13.49 (13.13–13.85) 12.16 (11.83–12.49)
West 5,322 20.72 (20.17–21.28) 19.46 (18.93–20.00)
ALD, alcohol-associated liver disease; CI, confidence interval.
areas. Increases in ALD mortality rates are seen in almost every
age and race/ethnicity since 2006, which may be due to increased
alcohol use during times of economic uncertainty that proceeded
the US recession of 2008 (17–20).
Worldwide, alcohol use ranks seventh in risk factors that lead
to death and disability, accounting for 2.8million deaths annually
(21). In the United States, AUD accounts for more years lived
with disability than dementia or asthma (22). Recent publications
have reported increased mortality in the United States from
chronic liver disease and cirrhosis, including ALD (2,7,8). Al-
though 1 study reported on the increasing relative risk of ALD
mortality in Americans aged 24–34 years, our study is focused on
the burden of ALD from a population health perspective, i.e., the
underlying risks by presenting ARDs (8). Our work highlights
important disparities in the risk of ALDmortality by sex, age, and
race. Specifically, the underlying risk is higher in men compared
with women, and the risks are higher in middle-aged and older
age groups. With regard to patterns over time, the growing risk
with the greatest population health impact is occurring in both
men and women who are middle aged and older. As has been
pointed out previously, increasing ALD mortality mirrors
declines seen inmental health and ability towork and increases in
suicides and drug overdoses seen in middle-aged Americans (2).
Although these trends preceded the economic downturn in the
first decade of the 21st century, they may be related to financial
insecurity prior to the recession.
ALD mortality and recent rate increases were particularly
marked among Native Americans. Given these trends, studying
ALD in this underserved population should be high priority.
Compared with whites, Native Americans had 2 times the ALD
mortality in 2017 and, in women, 2 times higher annual mortality
rate increases, indicative of a public health crisis in this population.
There are several potential explanations for these strikingly high
mortality figures inNative Americans. First, levels of alcohol use or
Figure 1. Mortality from ALD in the United States from 1999 to 2017 by sex. Trends in mortality rates and significant changes in slope determined by
Joinpoint analysis. ALD, alcohol-associated liver disease.
In men, Native Americans (ARD 0.3, 95% CI 0.1–0.6, 
1999–2017) and white/non-Hispanics (ARD 0.4, 95% CI 0.3–0.4, 
2006–2017) had the largest recent increases in ALD mortality 
(Figure 3). Conversely, ALD death rates decreased in black/non-
Hispanics by 0.7 per 100,000 (95% CI 20.9 to 20.5) from 1999 to 
2006 and was stable (ARD 0.0, 95% CI 0.0–0.2) from 2006 to 2017.
Mortality from ALD higher and increasing disproportionately in 
rural areas
In 2017, age-adjusted ALD mortality was higher in rural com-
pared with urban inhabitants (6.5 vs 5.4/100,000 in women and 
14.7 vs 12.8/100,000 in men). The West region had the highest 
ALD death rate in 2017 with 8.9/100,000 (95% CI 8.5–9.3) in 
women and 19.5/100,000 (95% CI 18.9–20.0) in men.
In women, the annual rise in ALD mortality was also higher in 
rural areas (ARD 0.4, 95% CI 0.3–0.6, 2013–2017) compared with 
urban areas (ARD 0.2, 95% CI 0.2–0.3, 2008–2017). Similar 
trends were seen in men with a 0.8 per 100,000 yearly increase in 
ALD mortality rates in rural areas. The largest regional increases 
were seen in Midwestern women (2013–2017 ARD 0.4, 95% CI 
0.2–0.7) and men (2011–2017 ARD 0.4, 95% CI 0.3–0.5) and men 
from the South (2011–2017 ARD 0.5, 95% CI 0.4–0.6). Annual 
mortality rates in men and women and all demographic sub-
categories are detailed in the supplemental tables (see Supple-
mentary Digital Content 2, http://links.lww.com/AJG/B306).
DISCUSSION
Life expectancy in the United States is decreasing in large part due 
to an epidemic of addiction (1). Our results highlight the large and 
growing role of ALD in these concerning trends and identify 
subpopulations at highest risk of ALD mortality who may benefit 
from targeted public health interventions. ALD mortality is 
particularly high and increasing in middle-aged men and women, 
Native Americans, non-Hispanic whites, and those living in rural
Table 3. Trends in mortality from ALD among women in the United States, 1999–2017
Trend 1 Trend 2 Trend 3
AAPC (1999–2017)Years ARD (95% CI) APC (95% CI) Years ARD (95% CI) APC (95% CI) Years ARD (95% CI) APC (95% CI)
Overall 1999–2006 0.01 (20.01 to 0.04) 0.00 (21.07 to 1.09) 2006–2013 0.16a (0.13 to 0.19) 3.98a (3.20 to 4.78) 2013–2017 0.30a (0.23 to 0.37) 6.02a (4.45 to 7.60) 3.08a (2.54 to 3.63)
Age groups (y)
25–34 1999–2003 20.05a (20.08 to 20.01) 27.77 (215.42 to 0.58) 2003–2009 0.04a (0.02 to 0.07) 13.27a (10.21 to 16.40) 2009–2017 0.10a (0.09 to 0.12) 7.58 (23.25 to 19.63) 6.07a (2.95 to 9.28)
35–44 1999–2012 20.01 (20.03 to 0.01) 20.17 (20.89 to 0.55) 2012–2017 0.27a (0.18 to 0.37) 8.18a (5.08 to 11.38) 2.08a (1.19 to 2.98)
45–54 1999–2005 0.16a (0.05 to 0.28) 2.65a (0.26 to 5.09) 2005–2017 0.33a (0.28 to 0.37) 4.33a (2.91 to 5.76) 3.76a (2.58 to 4.96)
55–64 1999–2008 0.06 (20.03 to 0.14) 0.68 (21.10 to 2.49) 2008–2017 0.55a (0.47 to 0.64) 6.86a (5.91 to 7.81) 4.06a (3.18 to 4.96)
65–74 1999–2011 20.02 (20.06 to 0.02) 20.31 (21.27 to 0.66) 2011–2017 0.31a (0.2 to 0.42) 6.19a (3.93 to 8.50) 1.81a (0.92 to 2.71)
75–84 1999–2017 0.01 (20.02 to 0.03) 0.15 (20.68 to 0.99) 0.15 (20.68 to 0.99)




1999–2006 0.06a (0.03 to 0.09) 1.90a (0.97 to 2.84) 2006–2013 0.19a (0.16 to 0.23) 4.74a (3.68 to 5.81) 2013–2017 0.39a (0.31 to 0.47) 6.92a (5.18 to 8.68) 4.10a (3.51 to 4.70)
Black/non-
Hispanic
1999–2006 20.25a (20.33 to 20.17) 27.19a (29.35 to 24.98) 2006–2017 0.10a (0.07 to 0.13) 3.20a (2.02 to 4.38) 20.97 (22.01 to 0.07)
Hispanic 1999–2005 20.06 (20.17 to 0.05) 21.64 (25.09 to 1.93) 2005–2017 0.11a (0.08 to 0.14) 3.02a (2.09 to 3.95) 1.44a (0.21 to 2.68)
Native American 1999–2005 20.14 (20.61 to 0.32) 21.18 (25.34 to 3.16) 2005–2017 0.76a (0.61 to 0.91) 3.54a (2.74 to 4.34) 2.21a (0.98 to 3.44)
Urbanization
Urban 1999–2008 0.03 (0.00 to 0.05) 20.00 (21.15 to 1.15) 2008–2017 0.22a (0.19 to 0.25) 4.60a (4.10 to 5.09) 2.78a (2.28 to 3.29)
Rural 1999–2003 0.04 (20.08 to 0.15) 0.55 (25.71 to 7.23) 2003–2013 0.17a (0.13 to 0.21) 4.14a (3.23 to 5.07) 2013–2017 0.44a (0.28 to 0.60) 7.58a (4.38 to 10.88) 4.29a (3.02 to 5.57)
Region
Northeast 1999–2006 20.04 (20.09 to 0.01) 21.39 (23.31 to 0.57) 2006–2017 0.13a (0.11 to 0.16) 4.96a (4.07 to 5.87) 2.44a (1.58 to 3.32)
Midwest 1999–2007 0.07a (0.03 to 0.10) 1.61 (21.91 to 5.25) 2007–2014 0.18a (0.11 to 0.24) 4.28a (2.76 to 5.81) 2014–2017 0.43a (0.21 to 0.65) 8.28a (4.50 to 12.19) 4.40a (3.05 to 5.76)
South 1999–2009 0.00 (20.03 to 0.04) 20.25 (21.71 to 1.24) 2009–2017 0.22a (0.17 to 0.27) 5.94a (4.68 to 7.22) 2.80a (1.91 to 3.70)
West 1999–2005 0.01 (20.10 to 0.13) 0.54 (21.69 to 2.83) 2005–2017 0.27a (0.22 to 0.31) 3.66a (3.01 to 4.32) 2.61a (1.81 to 3.42)
Reported mortality rates are age adjusted for all subcategories except for age groups.
AAPC, average APC; ALD, alcohol-associated liver disease; APC, annual percentage change; ARD, annual rate difference; CI, confidence interval.
aIndicates that slope is significantly different from zero at the alpha 5 0.05 level.
Table 4. Trends in mortality from ALD among men in the United States, 1999–2017
Trend 1 Trend 2 Trend 3
AAPC (1999–2017)Years ARD (95% CI) APC (95% CI) Years ARD (95% CI) APC (95% CI) Years ARD (95% CI) APC (95% CI)
Overall 1999–2006 20.12a (20.22 to 20.02) 21.64a (22.87 to 20.39) 2006–2017 0.31a (0.26 to 0.36) 2.66a (2.27 to 3.05) 1.12a (0.75 to 1.66)
Age groups (y)
25–34 1999–2010 0.02a (0.00 to 0.04) 20.36 (24.32 to 3.75) 2010–2017 0.16a (0.11 to 0.20) 8.49a (6.83 to 10.17) 4.95a (3.21 to 6.73)
35–44 1999–2005 20.23a (20.34 to 20.13) 23.74a (25.51 to 21.95) 2005–2013 0.05 (20.03 to 0.13) 0.89 (20.72 to 2.53) 2013–2017 0.30a (0.09–0.51) 4.78a (1.08 to 8.61) 0.16 (20.94 to 1.27)
45–54 1999–2004 20.12 (20.35 to 0.11) 20.69 (22.26 to 0.90) 2004–2017 0.22a (0.17 to 0.28) 1.31a (0.96 to 1.66) 0.75a (0.28 to 1.21)
55–64 1999–2004 20.31a (20.62 to 20.01) 21.14 (22.85 to 0.61) 2004–2017 0.86a (0.79 to 0.92) 3.79a (3.47 to 4.12) 2.40a (1.90 to 2.90)
65–74 1999–2003 20.54a (20.98 to 20.1) 23.23a (26.07 to 20.30) 2003 to 2012 0.08 (20.06 to 0.22) 0.57 (20.43 to 1.57) 2012–2017 1.09a (0.83 to 1.36) 5.90a (4.22 to 7.61) 1.15a (0.31 to 2.00)
75–84 1999–2009 20.11a (20.22 to 20.01) 21.11a (22.14 to 20.05) 2009–2017 0.45a (0.31 to 0.60) 4.13a (2.77 to 5.51) 1.19a (0.42 to 1.96)




1999–2006 20.02 (20.11 to 0.07) 20.62 (21.89 to 0.67) 2006–2017 0.36a (0.31 to 0.41) 3.19a (2.79 to 3.60) 1.91a (1.44 to 2.38)
Black/non-
Hispanic
1999–2006 20.67a (20.88 to 20.46) 26.99a (28.99 to 24.93) 2006–2017 0.07 (20.01 to 0.15) 0.78 (20.30 to 1.87) 22.32a (23.27 to 21.35)
Hispanic 1999–2004 20.96a (21.52 to 20.40) 24.84a (27.74 to 21.84) 2004–2017 0.14a (0.04 to 0.24) 0.75a (0.16 to 1.34) 20.84 (21.70 to 0.04)
Native
American
1999–2017 0.32a (0.09 to 0.56) 1.08a (0.30 to 1.87) 1.08a (0.30 to 1.87)
Urbanization
Urban 1999–2005 20.20a (20.32 to 20.08) 21.85a (23.05 to 20.63) 2005–2017 0.27a (0.23 to 0.31) 2.50a (2.12 to 2.88) 1.03a (0.59 to 1.48)
Rural 1999–2002 20.36 (20.90 to 0.18) 23.45 (29.23 to 2.70) 2002–2013 0.24a (0.16 to 0.33) 2.36a (1.46 to 3.27) 2013–2017 0.75a (0.37 to 1.12) 5.62a (2.35 to 9.01) 2.08a (0.85 to 3.32)
Region
Northeast 1999–2005 20.20a (20.32 to 20.09) 22.73a (24.38 to 21.06) 2005–2017 0.19a (0.15 to 0.23) 2.52a (1.96 to 3.08) 0.74a (0.12 to 1.36)
Midwest 1999–2002 20.29 (20.57 to20.01) 23.49 (27.04 to 0.19) 2002–2011 0.18a (0.12 to 0.24) 2.18a (1.39 to 2.97) 2011–2017 0.44a (0.34 to 0.54) 4.24a (3.18 to 5.32) 1.89a (1.16 to 2.63)
South 1999–2004 20.27a (20.42 to 20.12) 22.89a (24.57 to 21.18) 2004–2011 0.07 (20.03 to 0.17) 0.81 (20.45 to 2.08) 2011–2017 0.51a (0.40 to 0.61) 4.86a (3.75 to 5.99) 1.09a (0.39 to 1.79)
West 1999–2004 20.17 (20.48 to 0.14) 20.92 (23.00 to 1.20) 2004–2017 0.32a (0.25 to 0.39) 1.80a (1.37 to 2.24) 1.04a (0.43 to 1.65)
Reported mortality rates are age adjusted for all subcategories except for age groups.
AAPC, average APC; ALD, alcohol-associated liver disease; APC, annual percentage change; ARD, annual rate difference; CI, confidence interval.
aIndicates that slope is significantly different from zero at the alpha 5 0.05 level.
abuse may be higher among Native Americans, although data on
alcohol use relative to other groups in this population are con-
flicting, with lower overall alcohol intake but more prevalent binge
drinking in Native American teenagers (23,24). Second, increased
mortality may be due to higher susceptibility to ALD in the Native
American population. Although small studies have failed to
demonstrate a difference in alcohol metabolism or levels of liver
alcohol dehydrogenase between whites and Native Americans,
there may be undiscovered genetic risk factors among this pop-
ulation (25). Third, Native American populationsmay have higher
levels of concomitant nonalcoholic fatty liver disease or hepatitis C
virus contributing to liver-related complications and deaths in
patients with ALD (26,27). Last, it may be that there is increased
coding of ALD mortality in this population. However, mis-
classification is unlikely to account for the outsized burden of ALD
mortality we observed in Native Americans.
Although ALD mortality rates were lower among women
and nonwhite ethnicities, data on AUD indicate that this may
change in the future. The prevalence of AUD continues to
increase in the US population with the most pronounced
increases among women, nonwhite ethnicities, older adults,
and those with lower education and income levels (28). These
trends raise concern that mortality from ALD will only con-
tinue to increase in the United States, particularly among these
at-risk subgroups.
Abstinence from alcohol is the mainstay of treatment for
ALD but patient underreporting impedes detection (29). Failure
to address comorbid psychiatric comorbidities, which are
common in the setting of substance use disorders, also limits
detection and treatment (30). The difficulties in screening for
AUD and its end-organmanifestations are reinforced by studies
showing that less than half of American adults are receiving
recommended screening for alcohol misuse and that ALD is
diagnosed at a later stage compared with other etiologies of liver
disease (31,32). In addition to issues with underdiagnosis,
treatments are limited in ALD. Treatment of AUD with
Figure2.Mortality fromALD in theUnited States from1999 to 2017 inwomen (left panel) andmen (right panel) by age groups. Trends inmortality rates and
significant changes in slope determined by Joinpoint analysis. ALD, alcohol-associated liver disease.
Figure 3.Mortality from ALD in the United States from 1999 to 2017 in women (left panel) andmen (right panel) by race/ethnicity. Trends in mortality rates
and significant changes in slope determined by Joinpoint analysis. ALD, alcohol-associated liver disease.
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Study Highlights
WHAT IS KNOWN
3 Life expectancy among Americans is decreasing.
3 Although overshadowed by opioid-related deaths, ALD
mortality is high and is contributing to decreasing life
expectancy in the United States.
WHAT IS NEW HERE
3 ALDmortality rates in theUnitedStateswerehigher in2017 than
any other year since 1999 and are increasing in recent years.
3 Current ALD mortality rates and recent increases are
particularly pronounced in middle-aged adults, Native
Americans, and non-Hispanic/whites.
3 Public health interventions should be designed to target these
high-risk groups.
psychosocial interventions is often insufficient, and medications 
to induce and maintain abstinence have safety concerns or in-
sufficient evidence of efficacy in patients with ALD (29,33,34). 
There have been few advances in alcohol-related hepatitis since 
prednisolone was first recommended in 1971 (35). Last, patients 
may encounter barriers to addiction treatment, potentially due 
to the associated societal stigma.
The increase in ALD mortality raises the question of 
whether we are experiencing a larger epidemic of addiction and 
self-medication concomitant with increasing rates of opioid 
misuse. This is suggested by similarities in demographic 
characteristics of those affected by opioids and ALD, including 
higher mortality rates in rural areas and non-Hispanic whites 
(9). There are innovative initiatives in place to address the 
opioid epidemic; however, alcohol receives far less attention 
(36). Given the potential for considerable overlap in the burden 
of alcohol and opioid abuse, it may be possible to leverage 
resources allocated to address the opioid crisis to simulta-
neously address AUD.
We have estimated the absolute and changing risk of ALD 
mortality using population-based data and have stratified by age, 
sex, and race to generate actionable estimates of the burden of 
disease. These nationally representative, up-to-date data on the 
mortality burden of ALD may help guide future public health 
interventions. However, this analysis has potential limitations. 
First, our estimates of mortality are based on death certificates, 
which may be inaccurate (37). We decreased the risk of ascer-
tainment bias by limiting our analysis to the underlying cause of 
death, thus generating the most conservative estimate possible. 
Second, our estimates of ALD mortality likely underestimate its 
true burden because our definition did not capture deaths from 
hepatocellular carcinoma or liver disease from multiple etiologies 
(e.g., hepatitis C virus and ALD). This is emphasized by previous 
studies demonstrating that cirrhosis-related deaths are under-
estimated (37). We chose to limit our definition to ALD alone to 
maximize its specificity for identifying liver-related deaths at-
tributable to alcohol use.
In conclusion, mortality from ALD has increased among men 
and women of almost every age and race in the United States with 
the exception of non-Hispanic blacks. As such, a comprehensive 
effort to address ALD mortality in the United States is needed 
starting with better therapeutic interventions, strategies to ad-
dress excessive alcohol consumption (e.g., alcohol taxes and dram 
shop liability), and public health interventions. Given the overlap 
between populations affected by AUD and opioid abuse, in-
frastructure being developed to address the opioid epidemic 
could be leveraged to help address ALD.
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